Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TRPH-222 |
Synonyms | |
Therapy Description |
TRPH-222 is an antibody-drug conjugate that consists of a CD22 antibody linked to a maytansinoid payload, which may inhibit tumor growth (Cancer Res 2018;78(13 Suppl):Abstract nr 835). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TRPH-222 | TRPH222|TRPH 222 | CD22 Immune Cell Therapy 15 | TRPH-222 is an antibody-drug conjugate that consists of a CD22 antibody linked to a maytansinoid payload, which may inhibit tumor growth (Cancer Res 2018;78(13 Suppl):Abstract nr 835). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03682796 | Phase I | TRPH-222 | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | Completed | USA | CAN | 0 |